Matsuda Masaru's Form 4 filing
Arcutis Biotherapeutics, Inc. (ARQT) · filed Dec 3, 2024
- Accession no.
- 0001787306-24-000168
- Filed
- Dec 3, 2024
- Trade date
- May 31-Nov 30, 2024
- Filing delay
- 186 daysLate
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions. Open-market purchases total $18.5K. It was filed 186 days after the trade, past the 2-business-day deadline.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Matsuda MasaruCIK 0001798679 | Officer (See Remarks) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| May 31, 2024 | Common Stock | PPurchaseAcquired | +4,000 | $1.69 | +$6,760 | 185,373 | Direct | |
| Nov 30, 2024 | Common Stock | PPurchaseAcquired | +1,657 | $7.11 | +$11,781.27 | 187,030 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.
Remarks
Reporting Person's title: Senior Vice President General Counsel and Corporate Secretary